HAMLET B — Hamlet BioPharma AB Share Price
Last trade - 00:00- SEK559.38m
- SEK558.15m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 12.2 | ||
| Price to Tang. Book | 5,176.61 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -52.84% | ||
| Return on Equity | -73.84% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hamlet BioPharma AB, formerly Hamlet Pharma AB, is a Sweden-based pharmaceutical company that develops new drugs for the treatment and prevention of cancer. The Company provides new therapeutic solutions using a peptide-based molecular approach for targeting and killing tumour cells with greater precision. Its synthetic drug candidate Alpha1H kills tumor cells quickly, both in the laboratory and in animal models and in treated patients, where the response can be measured already within a few hours. The other product BAMLET kills cancer cells and has shown effects against growing tumor tissue, especially for colon cancer. Hamlet Pharma is therefore driving the development of BAMLET as a future drug against cancer. The Company intends to establish production of BAMLET primarily for clinical studies of the treatment/prevention of colon cancer in the gastrointestinal tract and oral cancer in the oral cavity.
Directors
- Catharina Svanborg CHM
- Mats Persson CEO (58)
- Bill Hansson DRC
- Christer Kohler DRC (72)
- Helena Lomberg DRC
- Bengt Westermark DRC (74)
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 29th, 1999
- Public Since
- October 23rd, 2015
- No. of Employees
- 7
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- AktieTorget Stock Exchange
- Shares in Issue
- 238,035,864
- Address
- Klinikgatan 32, LUND, 222 42
- Web
- https://hamletbiopharma.com/
- Phone
- +46 40122500
- Auditors
- Moore Malmo AB
Upcoming Events for HAMLET B
Similar to HAMLET B
Abera Bioscience AB
AktieTorget Stock Exchange
Aptahem AB
AktieTorget Stock Exchange
Arcede Pharma AB
AktieTorget Stock Exchange
Carbiotix AB (publ)
AktieTorget Stock Exchange
Chosa Oncology AB
AktieTorget Stock Exchange
FAQ
As of Today at 19:10 UTC, shares in Hamlet BioPharma AB are trading at SEK2.35. This share price information is delayed by 15 minutes.
Shares in Hamlet BioPharma AB last closed at SEK2.35 and the price had moved by -20.7% over the past 365 days. In terms of relative price strength the Hamlet BioPharma AB share price has underperformed the FTSE Global All Cap Index by -27.36% over the past year.
There is no consensus recommendation for this security.
Hamlet BioPharma AB does not currently pay a dividend.
Hamlet BioPharma AB does not currently pay a dividend.
Hamlet BioPharma AB does not currently pay a dividend.
To buy shares in Hamlet BioPharma AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK2.35, shares in Hamlet BioPharma AB had a market capitalisation of SEK559.38m.
Here are the trading details for Hamlet BioPharma AB:
- Country of listing: Sweden
- Exchange: AKT
- Ticker Symbol: HAMLET B
Based on an overall assessment of its quality, value and momentum Hamlet BioPharma AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hamlet BioPharma AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +25.39%.
As of the last closing price of SEK2.35, shares in Hamlet BioPharma AB were trading +22.16% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Hamlet BioPharma AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK2.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Hamlet BioPharma AB's management team is headed by:
- Catharina Svanborg - CHM
- Mats Persson - CEO
- Bill Hansson - DRC
- Christer Kohler - DRC
- Helena Lomberg - DRC
- Bengt Westermark - DRC